Characteristic | Group A (n = 143) | Group B (n = 67) | P value |
---|---|---|---|
Male, no. (%) | 116 (81) | 54 (80) | NS |
Age, years | 42 (20-68) | 45 (37-66) | NS |
Body mass index, kg/m2 | 24 (22-32) | 25 (21-30) | NS |
V iral Load | Â | Â | Â |
   -<400.000 UI/ml | 83(58) | 22(33) | < 0.01 |
   ->400.000 UI/ml | 60(42) | 45(67) | < 0.01 |
Route of Trasmission | Â | Â | Â |
   -Intravenous drug use | 94(66) | 48(72) | NS |
   -Transfusion | 17(12) | 9 (13) | NS |
   - Unknown | 32(22) | 10(15) | NS |
Alanine aminotransferase, IU/L | 150(98-255) | 145 (96-208) | NS |
HCV genotype 2, n (%) | 79 (55) | 37 (55) | NS |
HCV genotype 3, n (%) | 64 (45) | 30 (45) | NS |
Cirrhosis (Ishak stage 5-6) n(%) | 13 (9) | 8 (12) | NS |
Bridging fibrosis (Ishak stage 3-4) n(%) | 26 (18) | 15 (22) | NS |